Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Emulsion · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Ophthalmic Emulsion | DRUG | - |
* Eighteen years or older * Diagnosis of moderate to severe dry eyes for at least 6 months and meet one or all of the following criteria: * Diagnosis of autoimmune disorder * Female 65 years of age or older
Emulsion is an investigational small molecule being studied for the treatment of keratoconjunctivitis sicca, commonly known as dry eye syndrome. It is being developed by AbbVie Inc. (ABBV) and is currently in Phase 3 clinical development.
Emulsion is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 3 clinical trials for the treatment of keratoconjunctivitis sicca.
Emulsion is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of keratoconjunctivitis sicca.
Emulsion has one completed Phase 3 clinical trial registered under NCT00025818. This six-month study enrolled 290 participants with moderate or severe dry eye syndrome, including patients with keratoconjunctivitis sicca, Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic scleroderma.
The Phase 3 clinical trial for Emulsion, NCT00025818, was a randomized, double-blind study. The trial did not use a control group, meaning all participants received the study drug without a placebo or active comparator.